Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05505734 · ClinicalTrials.gov registry record · Phase 3

A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma

A Phase 3 study of Asthma, sponsored by Bond Avillion 2 Development.

Completed
Registry status
Phase 3
Development phase
2,516
Enrollment target
20
Study locations

NCT05505734: Completed Phase 3 study of Asthma, sponsored by Bond Avillion 2 Development.

NCT05505734 is a Phase 3 study of Asthma that has completed, run by Bond Avillion 2 Development. The registered enrollment target is 2,516 participants, above the 1,557-participant average among 374 other Asthma trials with a reported enrollment target (62% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05505734, a Phase 3 study of Asthma, has completed, sponsored by Bond Avillion 2 Development.

COMPLETED
Registry status
Phase 3
Development phase
2,516 participants
Enrollment target
20
Study locations

Study Summary

This is a US study comparing the efficacy and safety of BDA MDI \[Budesonide/Albuterol Sulfate (BDA) metered dose inhaler (MDI)\] with AS \[Albuterol Sulfate\] MDI, both are administered as needed for up to 12 months.

Conditions Studied

Asthma

Interventions

  • DRUG BDA MDI
  • DRUG AS MDI

Study Locations (20)

Georgia

  • Centricity Research - Columbus
  • Centricity Research - Columbus
  • Centricity Research - Columbus
  • Centricity Research - Columbus
  • Lifeline Primary Care - Lilburn
  • Javara Inc./Privia Medical Group Georgia, LLC - Savannah

California

  • Kern Research Inc. - Bakersfield
  • Science 37 - Culver City
  • Antelope Valley Clinical Trials - Lancaster
  • Allergy & Asthma Medical Group and Research (AAMGRC) - Allergy, Asthma and Immunology - San Diego
  • Clinical Research of California - Walnut Creek

Arizona

  • One of a Kind Clinical Research Center - Paradise Valley
  • Fiel Family and Sports Medicine/CCT Research - Tempe

Colorado

  • Asthma and Allergy Associates - Colorado Springs
  • Velocity Clinical Research, Denver - Denver

Florida

  • Helix Biomedics - Boynton Beach
  • Allergy and Asthma Diagnostic Treatment Center - Tallahassee

Alabama

  • Pulmonary Associates of Mobile PC - Mobile

Idaho

  • Velocity Clinical Research - Boise - Meridian

Indiana

  • Velocity Clinical Research - Valparaiso - Valparaiso

Trial Details

FieldValue
Enrollment Target 2,516 participants
Start Date 2022-09-02
Est. Completion 2024-08-22
Phase Phase 3

Sponsor

Bond Avillion 2 Development

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05505734

The ClinicalTrials.gov registry entry for NCT05505734 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,516 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,557-participant average among 374 other Asthma trials with a reported enrollment target (62% higher). The listed sponsor is Bond Avillion 2 Development, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which BDA MDI is the first listed.

NCT05505734 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Georgia, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT05505734 about?

NCT05505734 is a clinical study titled "A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma". This is a US study comparing the efficacy and safety of BDA MDI \[Budesonide/Albuterol Sulfate (BDA) metered dose inhaler (MDI)\] with AS \[Albuterol Sulfate\] MDI, both are administered as needed for up to 12 months.

What is the current status of trial NCT05505734?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,516 participants. The study started on 2022-09-02. Estimated completion is 2024-08-22.

What conditions does trial NCT05505734 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT05505734?

The interventions under investigation include: BDA MDI (DRUG), AS MDI (DRUG).

Who is sponsoring clinical trial NCT05505734?

This trial is sponsored by Bond Avillion 2 Development, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05505734 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Asthma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.